Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a daily capsule thicken thinning hair? a trial puts three doses to the test

NCT ID NCT06551818

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This clinical trial is testing whether a daily oral supplement called SesZen-Bio can improve hair thickness, density, and growth in people with mild to moderate androgenic alopecia (common pattern hair loss). About 72 adults aged 25 to 45 will be randomly assigned to one of three different doses of SesZen-Bio or a placebo, and neither they nor the researchers will know who gets what. The study measures changes in hair using a specialized imaging device, along with safety and tolerability.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SesZen-Bio capsules (three dosage formulations: 350 mg extract, 150 mg liposomal, 500 mg extract)
What this could lead to
If successful, this could point toward an oral supplement option to improve hair thickness, density, and growth in people with early-stage hair loss.
What could go wrong
This is an early exploratory study with a small number of participants, so results may not hold up in larger trials. The product may not outperform placebo, and side effects are not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

72 people

The number who actually took part.

Started

Sep 2024

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age: 25 to 45 years and above (both inclusive) at the time of consent. 2. Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females). 3. Females of childbearing potential must have a self-reported negative urine pregnancy. 4. Patient is in good general health as determined by the Investigator on the basis of medical history. 5. Patients having mild to moderate Androgenic Alopecia (Grade I to III) during clinical study and grade will be evaluated by the dermatologist by using Norwood-Hamilton classification and Ludwig pattern scale for female. 6. Female with 40-50 counts and male with 25 -30 counts of hair fall at screening. 7. Patient is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study. 8. If the patient is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation. 9. Patients are willing to give written informed consent and are willing to follow the study procedure. 10. Patients who commit not to use any other medicated/ prescription shampoos/hair care products (containing Minoxidil), any other hair growth products or hair colour or dye, other than the test products for the entire duration of the study. 11. Willing to consume test products throughout the study period. 12. Patient is willing and able to follow and allow study staff to performed study test methods. 13. Patient is willing and able to follow the study directions, to participate in the study, returning for all specified visits. 14. Patient must be able to understand and provide written informed consent to participate in the study. Exclusion Criteria: 1. Patient have history of severe hair fall due to any clinically significant problems like anaemia, thyroid problems. 2. Patient have history of any dermatological condition of the scalp other than hair loss and dandruff. 3. Patient have history of any prior hair growth procedures (e.g. hair transplant or laser). 4. Patient who had taken topical treatment of hair loss for at least 4 weeks. 5. Patient who had taken any systemic treatment for at least 3 months. 6. History of alcohol or drug addiction. 7. Patient having history or resent condition of irritated or visibly inflamed scalp or severe scalp disease. 8. Patient who is currently participating in or planning on starting weight loss program that may result in a significant change in overall body weight. 9. Pregnant or breast feeding or planning to become pregnant during the study period. 10. History of chronic illness which may influence the cutaneous state. 11. Patient have participated any clinical research study related to hair care products. 12. Patient have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Androgenic alopecia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • NovoBliss Research Pvt Ltd

    Ahmedabad, Gujarat, 382481, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.